Five IPOs are scheduled for the week of Jan. 28. The full IPO calendar is available here.
Gladstone Land (NASDAQ:LAND)
Based in McLean, Va., Gladstone Land (LAND) scheduled a $50 million IPO with a market capitalization of $91 million at $15 per share for Tuesday, Jan. 29, 2013. In the current IPO attempt, LAND expects to sell 54% of the company, which is relatively high and is a sign of weakness.
Stemline Therapeutics (NASDAQ:STML)
Based in New York, N.Y., Stemline Therapeutics scheduled a $25 million IPO with a market capitalization of $65 million at a price range midpoint of $11 for Tuesday, Jan. 29, 2013. STML is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. STML made stunning preclinical results in two patients.
KaloBios Pharmaceuticals (NASDAQ:KBIO)
Based in south San Francisco, Calif., KaloBios Pharmaceuticals (KBIO) scheduled a $51 million IPO with a market capitalization of $238 million at a price range midpoint of $13 for Thursday, Jan. 31, 2013. KBIO is a biopharma company focused on monoclonal antibody therapeutics. KBIO has a major partnership with the vaccines division of the Sanofi Group (NYSE:SNY), which has a market cap of $126 billion.
TRI Pointe Homes (NYSE:TPH)
Based in Irvine, Calif., TRI Pointe Homes (TPH) scheduled a $173 million IPO with a market capitalization of $474 million at the price range midpoint of $15 for Thursday, Jan. 31, 2013. TPH is a new homebuilding company formed by a very experienced management team lead by Barry Stenlicht. Sternlicht has been the chairman and CEO of Starwood Capital Group since its formation in 1991. He also has been the chairman of the board of directors and the CEO of Starwood Property Trust (NYSE:STWD), a New York Stock Exchange-listed company, since its formation in 2009.
Based in New York, N.Y., Zoetis (ZTS) scheduled $2 billion IPO with a market capitalization of $11.75 billion at a price range midpoint of $23.50 for Friday, Feb. 1, 2013. ZTS is a spin-off of Pfizer's (NYSE:PFE) animal health business. ZTS is the largest player in an industry that expects 6% annual compound growth in revenues.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.